Correction to: Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom (BMC Gastroenterology, (2020), 20, 1, (296), 10.1186/s12876-020-01441-6)

Ahmed B. Bayoumy, Elsa L.S.A. van Liere, Melek Simsek, Ben Warner, Aathavan Loganayagam, Jeremy D. Sanderson, Simon Anderson, Jonathan Nolan, Nanne K. de Boer, Chris J.J. Mulder, Azhar Ansari

Research output: Contribution to journalComment/Letter to the editorAcademic


After publication of this article [1], the authors reported three adjustments: 1. Competing interests: the travel grants were paid by HLW Pharma instead of TEVA Pharma. 2. TGN-units all over the manuscript have to be adjusted from pmol/8 × 105 RBC to pmol/8 × 108 RBC. 3. Some minor textual adjustments. The original article [1] has been updated.

Original languageEnglish
Article number208
JournalBMC Gastroenterology
Issue number1
Publication statusPublished - Dec 2022

Cite this